Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced that it intends to offer and sell, subject to market and other conditions, 13,000,000 shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Morgan Stanley
View HTML
Toggle Summary ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
View HTML
Toggle Summary Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products
Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75 million upfront payment, up to $100 million in research support, a co-commercialization option, and potential future opt-in fees, milestones and royalties
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David Johnston , chief financial officer, will present at the upcoming Canaccord Genuity Growth Conference .
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results
Data Presented at ASCO Support Broad Potential of Mirvetuximab Soravtansine in Ovarian Cancer Sanofi and Debiopharm Transactions Strengthen Cash Position Conference Call to be Held at 8:00am ET Today WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc .
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 28, 2017 , to discuss its second quarter
View HTML
Toggle Summary ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia
Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities Dose-dependent biological and anti-leukemia activity observed WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
View HTML
Toggle Summary ImmunoGen and Sanofi Amend License Agreements
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , president and chief executive officer, will present at the upcoming Jefferies 2017 Global Healthcare
View HTML